Stryker (SYK) Stock After Recent Pullback And DCF Upside Potential - simplywall.st
📉 Stryker stock is down 15.6% over the past year but has rebounded with an 8.5% gain in the last week.
💰 The company generated approximately $4.6 billion in free cash flow over the latest twelve months.
📊 DCF analysis estimates an intrinsic value of $379.17 per share, implying a 12.8% discount to current price.
📈 Stryker trades at a P/E ratio of 37.97x, which is higher than the industry average of 25.90x.
🎯 The proprietary Fair Ratio model suggests a suitable P/E of 31.39x, indicating potential overvaluation on earnings multiples.
🧠 Investors can use Simply Wall St's 'Narratives' tool to customize revenue and margin assumptions for fair value estimation.
📅 Analysts provide explicit free cash flow estimates extending through the year 2028.
Bullish Signals
- DCF model indicates Stryker is undervalued by 12.8% with an intrinsic value of $379.17 compared to the current price of $330.52.
- The company has demonstrated long-term growth, showing gains over both 3 and 5 year periods despite recent annual declines.
- Analysts provide explicit free cash flow projections extending out to 2028, indicating a stable outlook for future earnings generation.
Risk Factors
- Stryker trades at a P/E ratio of 37.97x, which is significantly higher than the Medical Equipment industry average of 25.90x and peer average of 28.45x.
- The proprietary Fair Ratio model suggests a suitable P/E of 31.39x, implying the stock may be pricing in excessive optimism relative to its risk profile.
Full Analysis
Stryker Corporation (NYSE: SYK) recently experienced a share price pullback of 5.1% year-to-date and 15.6% over the past year, despite an 8.5% gain in the last week. The stock currently trades at $330.52 per share, presenting a mixed valuation picture depending on the analytical framework used.
A Discounted Cash Flow (DCF) analysis projects Stryker's intrinsic value at $379.17 per share based on free cash flow estimates extending to 2035. This model suggests the stock is undervalued by approximately 12.8%, as the current price is below the calculated fair value derived from future cash projections.
However, traditional valuation metrics indicate a premium multiple. Stryker trades at a Price-to-Earnings (P/E) ratio of 37.97x, which is significantly higher than the Medical Equipment industry average of 25.90x and the peer group average of 28.45x. The company's proprietary 'Fair Ratio' model suggests a suitable P/E of 31.39x, implying the stock may be overvalued relative to its earnings growth expectations.
The article concludes by highlighting Simply Wall St's 'Narratives' tool, which allows investors to build custom financial models with varying assumptions for revenue and margins. This approach can reconcile the divergence between the optimistic DCF valuation and the conservative P/E multiple, offering a range of potential fair values from $315 to $465.
